News Quantified

Stock Stats

News Stats


All News	{{AllNewsCount}}
News Wires	{{NewsWiresCount}}
Media Monitoring	{{MoreOverCount}}
SEC Edgar Filings	{{SecEdgarFilingsCount}}
Upgrades	{{UpgradesCount}}
Downgrades	{{DowngradesCount}}
Initiated	{{InitiatesCount}}
Reiterated	{{ReiteratesCount}}
Last Earnings	{{LastEarnings}}
Last Earnings EPS	{{LastEps}}
Next Earnings	{{NextEarnings}}

Order Stats

Sub-Penny
{{SubPennyStr}}
Odd Lot
{{OddLotStr}}
Avg. bid-ask spread

{{GetAvgBidAskSpreadForScale}}
Avg. bid / ask size
{{GetAvgBidSizeForScale}} {{GetAvgAskSizeForScale}}

Shares at ask / bid
{{SharesAtAsk_AMP_Str}} {{SharesAtBid_AMP_Str}}
Off exchange
{{OffExchange}}

News

Immix Biopharma to Participate in the Jefferies Global Healthcare Conference

Immix Biopharma (IMMX) had its price target raised by Mizuho from $14.00 to $15.00. They now have an "outperform" rating on the stock.

Immix Biopharma Announces Enrollment Completion of BLA-Enabling Relapsed/Refractory AL Amyloidosis Trial NEXICART-2, and Upcoming Milestones

Immix Biopharma (IMMX) had its "market outperform" rating reaffirmed by Citizens Jmp. They now have a $23.00 price target on the stock.

Immix Biopharma (IMMX) had its price target raised by HC Wainwright from $12.00 to $15.00. They now have a "buy" rating on the stock.

Form ARS Immix Biopharma, Inc. For: Dec 31

Form DEFA14A Immix Biopharma, Inc.

Form DEF 14A Immix Biopharma, Inc. For: Apr 06

Form 8-K Immix Biopharma, Inc. For: Mar 30

Form 10-K/A Immix Biopharma, Inc. For: Dec 31

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}